Trial Profile
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Tamoxifen
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 05 Feb 2018 Status changed from active, no longer recruiting to completed.
- 08 Dec 2017 Planned End Date changed from 29 Dec 2017 to 2 Jan 2019.
- 09 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.